Isomorphic Labs raises $5bn while its first clinical trials wait

Reviewed byNidhi Govil

7 Sources

Share

Isomorphic Labs, Alphabet's AI drug-discovery company, raised a $5 billion Series C announced on Tuesday, co-led by Greenoaks and Sequoia Capital with Andreessen Horowitz among the new investors

4

2

3

. It is reportedly one of the largest funding rounds AI drug discovery has drawn this year

4

, and the money is meant to push the company's first drug candidates toward clinical trials

1

.

Source: Quartz

Source: Quartz

Every existing investor came back, and Alphabet itself put in more

4

1

7

. No valuation was disclosed, though Bloomberg reported earlier in November that Isomorphic would be valued at roughly $50 billion in the round

4

2

1

. It is the company's second giant round in six months, after a $2.1 billion Series B in May led by Thrive Capital

1

. Total funding stands at $7.7 billion per Market Screener

7

. The wider field is flush too: drug discovery startups have raised a record $23.2 billion this year, according to Dealroom's count, and OpenAI and Anthropic have both moved into the area

3

5

.

What the money is for

Hassabis said the money will scale the company's IsoDDE drug design engine, fund foundational biology models and push its first therapeutic programs toward clinical trials

3

5

6

. "What we're trying to build is a platform to do hundreds of drugs a year," he told Bloomberg

4

. That ambition sits against a current pipeline of more than 20 programs

4

5

.

Source: SiliconANGLE

Source: SiliconANGLE

Those programs have produced positive preclinical results in oncology and immunology, in Isomorphic's own work and with partners Eli Lilly, Novartis and Johnson & Johnson

4

1

5

. All of the results so far are preclinical

5

. The company also plans to expand beyond small-molecule drugs into biologics and to build the infrastructure for clinical development

4

6

. Sequoia partner Konstantine Buhler said his firm invested on the view that Isomorphic has discovered scaling laws for its models, meaning performance keeps improving as compute and data grow

4

.

The timeline that slipped

In January, Hassabis said the first clinical trials would begin by the end of 2026

4

5

. Asked this month, he declined to give an updated timeline, saying regulatory submissions for the first oncology program are on track and more news will come in 2027

4

5

. It is the fund's first raise since August, when Hassabis stepped back as Google DeepMind CEO to become DeepMind's chair and Alphabet's chief scientist, keeping the Isomorphic top job

4

3

1

. The Nobel laureate also faced a question about chip supply after Jensen Huang's resignation from Nvidia last week. "We've got very secure compute pipelines," he said, noting that Google designs its own AI chips

4

.

Source: The Next Web

Source: The Next Web

The $5 billion arrives before any clinical proof exists. No regulator has yet approved a drug designed by AI, according to Bloomberg's reporting

4

. Isomorphic's first trials would be among the first tests of whether an AI-designed molecule can clear that bar, per Bloomberg

4

.

© 2026 TheOutpost.AI All rights reserved